Neurocrine Biosciences Inc (NBIX)
Quick ratio
| Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash | US$ in thousands | 233,000 | 349,100 | 139,700 | 396,300 | 251,100 | 293,700 | 160,200 | 103,800 | 262,900 | 212,200 | 163,300 | 270,200 | 340,800 | 311,100 | 368,000 | 352,600 | 187,100 | 425,300 | 415,100 | 187,000 |
| Short-term investments | US$ in thousands | 843,100 | 878,900 | 899,200 | 814,300 | 780,500 | 801,400 | 816,500 | 790,800 | 726,400 | 587,200 | 485,000 | 394,700 | 370,500 | 454,800 | 516,900 | 521,100 | 613,900 | 519,400 | 533,200 | 584,700 |
| Receivables | US$ in thousands | 493,500 | 481,100 | 468,200 | 463,300 | 439,300 | 425,900 | 393,200 | 396,000 | 350,000 | 305,100 | 281,700 | 266,500 | 187,700 | 166,600 | 161,200 | 151,000 | 160,800 | 160,400 | 152,100 | 153,300 |
| Total current liabilities | US$ in thousands | 507,700 | 429,700 | 398,500 | 712,900 | 654,800 | 691,600 | 582,500 | 374,100 | 537,700 | 485,100 | 285,700 | 253,500 | 245,800 | 225,900 | 212,900 | 190,000 | 186,500 | 611,000 | 573,000 | 140,300 |
| Quick ratio | 3.09 | 3.98 | 3.78 | 2.35 | 2.25 | 2.20 | 2.35 | 3.45 | 2.49 | 2.28 | 3.26 | 3.67 | 3.66 | 4.13 | 4.91 | 5.39 | 5.16 | 1.81 | 1.92 | 6.59 |
December 31, 2024 calculation
Quick ratio = (Cash + Short-term investments + Receivables) ÷ Total current liabilities
= ($233,000K
+ $843,100K
+ $493,500K)
÷ $507,700K
= 3.09
The quick ratio of Neurocrine Biosciences Inc has experienced some fluctuations over the reporting periods provided. The quick ratio, which measures the company's ability to meet its short-term liabilities with its most liquid assets, was relatively high at 6.59 as of March 31, 2020. This indicates that Neurocrine Biosciences had a significant amount of liquid assets to cover its current liabilities at that time.
Subsequently, the quick ratio decreased to 1.92 by June 30, 2020, and further declined to 1.81 by September 30, 2020. These lower ratios suggest that Neurocrine Biosciences may have had a lower level of liquid assets compared to its current liabilities during these periods.
The quick ratio then improved to 5.16 as of December 31, 2020, and continued to stay relatively high through the first half of 2021, hovering around 5.39 and 4.91. This indicates that the company had a strong ability to cover its short-term obligations with its liquid assets during this period.
However, from September 30, 2021, to December 31, 2024, the quick ratio gradually decreased to a range between 2.20 and 3.98. This suggests that Neurocrine Biosciences' ability to cover its short-term liabilities with its most liquid assets decreased over time.
Overall, monitoring the trend of the quick ratio can provide insight into Neurocrine Biosciences' liquidity position and its ability to meet short-term obligations using its current assets.
Peer comparison
Dec 31, 2024